Investment Thesis
Matinas BioPharma is in severe financial distress with revenue collapsing 65.6% YoY to just $1.1M while burning $7M in operating cash flow quarterly. The company's negative gross profit structure, extreme operating margin of -635%, and rapidly depleting cash position indicate an unsustainable business model nearing a critical funding crisis.
Strengths
- Maintains positive stockholders equity of $4.8M providing limited balance sheet cushion
- Current ratio of 2.79x indicates short-term liquidity to cover immediate liabilities
- Zero long-term debt eliminates refinancing risk
Risks
- Revenue decline of 65.6% YoY signals complete loss of market traction and commercial viability
- Quarterly operating cash burn of $7M with only $4M cash remaining translates to <2 quarters of runway
- Massive negative margins (-943.9% net margin, -635% operating margin) indicate structural unprofitability with no clear path to positive returns
- No insider buying activity in last 90 days suggests management has no confidence in turnaround
- Clinical-stage pharma company with near-zero revenue indicating pipeline failure and failed commercialization
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Pipeline advancement and clinical trial outcomes
- Quarterly revenue stabilization or further deterioration
- Financing activities and dilution events
- Operating expense reduction measures
Financial Metrics
Revenue
1.1M
Net Income
-10.3M
EPS (Diluted)
$-2.00
Free Cash Flow
-7.2M
Total Assets
7.2M
Cash
4.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-635.0%
Net Margin
-943.9%
ROE
-214.2%
ROA
-143.5%
FCF Margin
-659.6%
Balance Sheet & Liquidity
Current Ratio
2.79x
Quick Ratio
2.79x
Debt/Equity
0.00x
Debt/Assets
33.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-02T10:08:10.791058 |
Data as of: 2025-12-31 |
Powered by Claude AI